Eyelashes provide biomechanical ocular surface protection by sensing debris and triggering the blink reflex, reducing ...

In the rapidly shifting landscape of multiple myeloma treatment, the roadmap for a patient diagnosed in 2026 looks vastly different than it did even a decade ago. In a recent interview with CURE, Dr.

explained that getting drugs into the brain is a major hurdle for glioblastoma, as the blood-brain barrier blocks most treatments.

Dr. Ajay K. Nooka, highlights how the evolution of therapy has moved the goalposts from simply achieving remission to pursuing a measurable cure.

A major obstacle is the blood-brain barrier, which Kunwar described as similar to “Saran Wrap” surrounding every blood vessel in the brain. This barrier evolved to protect the brain from foreign ...

In an interview with CURE, Dr. Susana Campos, clinical director of the Division of Gynecologic Oncology and assistant professor of medicine at Harvard Medical School, discussed re ...

After losing her eyelashes during chemotherapy, a two-time cancer survivor reflects on how their return reshaped her appreciation for a small but meaningful part of daily life.

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without Avastin, improves survival in platinum-resistant ovarian cancer.

Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without Avastin, improves survival in platinum-resistant ovarian cancer. The phase 3 KEYNOTE B96 trial showed ...

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.